Lilly Asia Ventures

Summary

In 2008 was created Lilly Asia Ventures, which is appeared as VC. The main office of represented VC is situated in the Shanghai. The venture was found in Asia in China.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lilly Asia Ventures, startups are often financed by OrbiMed, ARCH Venture Partners, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Vivo Capital, Temasek Holdings. In the next rounds fund is usually obtained by Hillhouse Capital Group, Qiming Venture Partners, Temasek Holdings.

The overall number of key employees were 4.

We can highlight the next thriving fund investment areas, such as Biotechnology, Health Care. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Alector, Betta Pharmaceuticals. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. Opposing the other organizations, this Lilly Asia Ventures works on 15 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 16 percentage points more often commits exit comparing to other companies. The average startup value when the investment from Lilly Asia Ventures is 500 millions - 1 billion dollars.